Long-acting hormonal contraception

Women's Health

Volumn 11, Issue 6, 2015, Pages 749-757

  Benagiano, Giuseppe ^a   Gabelnick, Henry ^b   Brosens, Ivo ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c LEUVEN INSTITUTE FOR FERTILITY AND EMBRYOLOGY   (Belgium)

Author keywords

Depot Depo Provera; Implanon; injectable contraceptives; intrauterine contraceptive systems; Jadelle; long acting contraceptives; Mirena; Noristerat; subcutaneous contraceptive implants; Uniplant

Indexed keywords

CONTRACEPTIVE AGENT; ELCOMETRINE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; LEVONORGESTREL BUTANOATE; LONG ACTING DRUG; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE ENANTATE; PROGESTERONE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BREAST CANCER; BREAST FEEDING; CANCER RISK; CONDOM USE; COPPER INTRAUTERINE DEVICE; DRUG BLOOD LEVEL; DRUG MILK LEVEL; ECTOPIC PREGNANCY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; NONHUMAN; OVULATION INHIBITION; REVIEW; SUSTAINED DRUG RELEASE; SYRINGE; ADVERSE EFFECTS; CONTRACEPTION; DELAYED RELEASE FORMULATION; FEMALE; PROCEDURES;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INTRAUTERINE DEVICES;

EID: 84951976843     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.15.68     Document Type: Review

References (50)

1. Goldzieher JW, Benagiano G. Long-acting injectable steroid contraceptives. In: Advances in Fertility Research (Volume 1). Mishell DR Jr (Ed.). Raven press, New York, USA, 75-115 (1982).
2. Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs 71(8), 969-980 (2011).
3. Halpern V, Stalter RM, Owen DH et al. Towards the development of a longer-acting injectable contraceptive: past research and current trends. Contraception 92(1), 3-9 (2015).
4. Winner B, Peipert JF, Zhao Q et al. Effectiveness of longacting reversible contraception. N. Engl. J. Med. 366(21), 1998-2007 (2012).
5. Benagiano G, Fraser I. The Depo-Provera debate: commentary on the article "Depo-Provera, a critical analysis". Contraception 24(5), 493-528 (1981).
6. Benagiano G, Diczfalusy E, Goldzieher JW et al. World Health Organization, Expanded Programme of Research, Development, Research training in Human Reproduction. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate: 1. Useeffectiveness. Contraception 15(5), 513-533 (1977).
7. Toppozada HK, Koetsawang S, Aimakhu VE et al. World Health Organization, Special Programme of Research, Development, Research training in Human Reproduction. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate given in two dosage regimens and depotmedroxyprogesterone acetate. Final report. Contraception 28(1), 1-20 (1983).
8. Thomas DB, Noonan EA. Collaborative study of neoplasia and steroid contraceptives: Breast cancer and depot medroxyprogesterone acetate: A multinational study. Lancet 338(8771), 833-838 (1991).
9. Bergendal A, Persson I, Odeberg J et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet. Gynecol. 124(3), 600-609 (2014).
10. Sang GW, Fotherby K, Howard H, Elder M, Bye PG. Pharmacokinetics of norethisterone oenanthate in humans. Contraception 24(1), 15-27 (1981).
11. Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception 79(5), 345-349 (2009).
12. Castle WM, Sapire KE, Howard K. Efficacy and acceptability of injectable medroxyprogesterone. Comparison of 3-montlily and 6 monthly regimens. S. Afr. Med. J. 53(21), 842-845 (1978).
13. Ruminjo JK, Sekadde-Kjgondu CB, Karanja IG et al. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception 72(2), 38-45 (2005).
14. Steroids 41, 242-425 (1983).
15. Special Programme of Research, Development and Department of Reproductive Health and Research. Biennial Technical Report 2005-2006. World Health Organisation, Geneva, 32-33 (2007).
16. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr. Rev. 31(1), 79-97 (2010).
17. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: A systematic review of the epidemiological evidence. Lancet Infect. Dis. 13(9), 797-808 (2013).
18. WHO. Hormonal contraception and HIV: technical statement. World Health Organization, Geneva, 2012. www.who.int
19. Polis CB, Westreich D, Balkus JE, Heffrone R. The Participants in the 2013 HC-HIV Observational Analysis Meeting. Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS 27(Suppl. 1), S35-S43 (2013).
20. Polis CB, Phillips SJ, Curtis KM et al. Hormonal contraceptive methods and risk of HIV acquisition in women: A systematic review of epidemiological evidence. Contraception 90(4), 360-390 (2014).
21. Sun M, Peipert JF, Zhao Q et al. Trends in contraceptive use among women with human immunodeficiency virus. Obstet. Gynecol. 120(4), 783-790 (2012).
22. Sivin I, Robertson D, Stern J et al. Norplant: reversible implant contraception. Stud. Fam. Plann. 11(2), 227-235 (1980).
23. Benagiano G, Gabelnick H, Farris M. Contraceptive devices: subcutaneous delivery systems. Expert Rev. Med. Devices 5(5), 623-637 (2008).
24. Sivin I, Campodonico I, Kiriwat O et al. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5 year randomized study. Hum. Reprod. 13(12), 3371-3378 (1998).
25. Croxatto HB, Makarainen N. Pharmacodinamics and efficacy of Implanon. Contraception 58(Suppl. 6), S91-S97 (1998)
26. Retraction: Rekers H, Affandi B. Contraception 70 [5], 433 [2004]).
27. McNicholas C, Maddipati R, Zhao Q et al. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet. Gynecol. 125(3), 599-604 (2015).
28. Guazzelli CA, De Queiroz FT, Barbieri M, Torloni MR, De Araujo FF. Etonogestrel implant in adolescents: evaluation of clinical aspects. Contraception 83(4), 336-339 (2011).
29. Graesslin O, Korver T. The contraceptive efficacy of Implanon®: A review of clinical trials and marketing experience. Eur. J. Contracept. Reprod. Health Care 13(Suppl. 1), 4-12 (2008).
30. Ireland LD, Goyal V, Raker CA, Murray A, Allen RH. The effect of immediate postpartum compared with delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding. Contraception 90(3), 253-258 (2014).
31. Modesto W, Dal Ava N, Monteiro I, Bahamondes L. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch. Gynecol. Obstet. 292(6), 1387-1391 (2015).
32. Bachorik A, Friedman J, Fox A et al. Adolescent and young adult women's knowledge of and attitudes toward etonogestrel implants. J. Pediatr. Adolesc. Gynecol. 28(4), 229-233 (2015).
33. Vollans SR, Grainger A, O'Connor P, Limb D. Hormonereleasing contraceptive implants: our experience of complex removals using preoperative ultrasound. Contraception 92(1), 81-83 (2015).
34. Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception 47(1), 97-105 (1993).
35. Devoto L, Kohen P, Barnhart K et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum. Reprod. 12(4), 708-713 (1997).
36. Barbosa IC, Maia H Jr, Coutinho E et al. Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. Contraception 74(6), 492-497 (2006).
37. Abdel-Aleem H, Abol-Oyoun el-S M, Shaaban MM et al. The use of nomegestrol acetate subdermal contraceptive implant, uniplant, during lactation. Contraception 54(5), 281-286 (1996).
38. Massai MR, Diaz S, Quinteros E et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception 64(6), 369-376 (2001).
39. Sivin I, Croxatto H, Bahamondes I et al. Two-year performance of a Nestorone-releasing contraceptive implant: A three-center study of 300 women. Contraception 69(2), 137-144 (2004).
40. Coutinho EM, Athayde C, Dantas C, Hirsch C, Barbosa I. Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women. Contraception 59(2), 115-122 (1999).
41. Ermini M, Carpino F, Petrozza V, Benagiano G. Distribution and effect on the endometrium of progesterone released from a progestasert device. Hum. Reprod. 4(3), 221-228 (1989).
42. Snowden R. The Progestasert and ectopic pregnancy. Br. Med. J. 2(6102), 1600-1601 (1977).
43. Nilsson C-G, Johansson EDB, Luukkainen TA. D-norgestrelreleasing IUD. Contraception 13(4), 503-514 (1976).
44. Faculty of family-planning and reproductive healthcare. FFPRHC Guidance. The levonorgestrel-releasing system (LNG-IUS) in contraception and reproductive health. J. Fam. Plann. Reprod. Health Care 30(2), 99-109 (2004).
45. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 42(1), 51-66 (1990).
46. Xiao B, Zeng T, Wu S, Sun H, Xiao N. Effect oflevonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception 51(6), 359-365 (1995).
47. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am. J. Obstet. Gynecol. 181(5 Pt 1), 1263-1269 (1999).
48. French RS, Cown FM, Mansour D et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraception: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol. Assess. 4, i-iv, 1-107 (2000).
49. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel releasing intrauterine device and Nova T. Contraception 46(6), 575-584 (1992).
50. Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxy-progesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler. Thromb. Vasc. Biol. 30(11), 2297-2300 (2010).